NCT06723015

Tau PET Outcomes With Anti-amyloid Immunotherapies

Study of Tau PET Outcomes in Patients Receiving Anti-amyloid Immunotherapies

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 135 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.

Conditions

• Cognitive Impairment, Mild
• Dementia, Mild
• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	18F-AV-1451	Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection. Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment..

Timeline

• Start date: 2025-11-04
• Primary completion: 2028-08-01
• Completion: 2028-08-01
• First posted: 2024-12-09
• Last updated: 2025-11-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study